Brainstorm Cell Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-10.3M | $-11.6M | $-17.2M | $-24.3M | $-24.5M | $-31.8M | $-23.3M | $-13.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $199.0K | $240.0K | $265.0K | $285.0K | $260.0K | $219.0K | $164.0K | $110.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.5M | $698.0K | $1.5M | $1.7M | $1.4M | $2.6M | $789.0K | $1.0M |
| Net Cash from Operating Activities | $-7.0M | $-9.1M | $-20.5M | $-19.3M | $-26.3M | $-35.2M | $-11.2M | $-12.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $18.0K | $29.0K | $330.0K | $378.0K | $473.0K | $369.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $12.0K | $2.2M | $998.0K | $323.0K | $-4.5M | $5.6M | $-1.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | $116.0K | — | — |
| Net Cash from Financing Activities | $6.9M | $8.0M | $19.0M | $238.0K | $7.0M | $76.9M | $5.2M | $12.1M |
| Net Change in Cash | $-95.0K | $-1.1M | $713.0K | $-18.1M | $-19.0M | $37.3M | $-406.0K | $-1.5M |
| Free Cash Flow | — | — | $-20.5M | $-19.3M | $-26.6M | $-35.6M | $-11.7M | $-12.8M |